Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Genomics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    107 result(s) found for: Genomics. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2018-003146-17 Sponsor Protocol Number: QGC001-2QG4 Start Date*: 2019-07-12
    Sponsor Name:Quantum Genomics
    Full Title: A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Vent...
    Medical condition: Prevention of left ventricular dysfunction after acute anterior myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-001618-39 Sponsor Protocol Number: CL08-ORY-2001_COVID-19 Start Date*: 2020-04-24
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A Phase II, randomized, open–label study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress...
    Medical condition: Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10003083 ARDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004509-29 Sponsor Protocol Number: QGC001-3QG1 Start Date*: 2020-04-27
    Sponsor Name:Quantum Genomics
    Full Title: A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects
    Medical condition: Treatment of hypertension (HTN) in difficult-to-treat and/or treatment resistant patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) PL (Completed) ES (Ongoing) CZ (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-016489-10 Sponsor Protocol Number: TPF-C-HIT Start Date*: 2010-08-23
    Sponsor Name:University of Heidelberg
    Full Title: Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanc...
    Medical condition: The study is a phase II study of induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003684-35 Sponsor Protocol Number: R2810-ONC-1763 Start Date*: 2018-07-10
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients wit...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) PL (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-001404-14 Sponsor Protocol Number: QGC001-3QG2 Start Date*: 2021-08-17
    Sponsor Name:Quantum Genomics
    Full Title: A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-...
    Medical condition: Treatment of patients with difficult-to-treat and/or treatment-resistant hypertension (HTN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10036695 Primary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) HU (Prematurely Ended) ES (Ongoing) CZ (Prematurely Ended) IT (Completed) NL (Prematurely Ended) BE (Completed) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-004860-12 Sponsor Protocol Number: ERCAVATAR2015 Start Date*: 2016-02-24
    Sponsor Name:Centro Nacional Investigaciones Oncológicas (CNIO)
    Full Title: Integrated Genomics and Avatar Mouse Models for Personalized Treatment of Pancreatic Cancer
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001570-42 Sponsor Protocol Number: AirGOs-2 Start Date*: 2018-05-07
    Sponsor Name:Helsinki University Hospital
    Full Title: Aggravated airway inflammation: research on genomics and optimal treatments (AirGOs)
    Medical condition: Acetylsalicylic acid (ASA-) exacerbated respiratory disease (AERD).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004603-35 Sponsor Protocol Number: REACH Start Date*: 2009-04-28
    Sponsor Name:University of Heidelberg
    Full Title: Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck. REACH-Study
    Medical condition: Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx or larynx (T2-4, NX, M0).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041849 Squamous cell carcinoma of the hypopharynx LLT
    9.1 10023856 Laryngeal squamous cell carcinoma LLT
    9.1 10031112 Oropharyngeal squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002140-88 Sponsor Protocol Number: CL04-ORY-2001 Start Date*: 2018-09-06
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer’s Disease (AD), Lewy Body Dementia (LBD)...
    Medical condition: Agression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10001488 Aggression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001436-54 Sponsor Protocol Number: CL06-ORY-2001 Start Date*: 2019-06-05
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A single-center, open-label, single-arm, 13-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in Alzheimer’s Disease (AD) – REIMAGINE-AD
    Medical condition: Aggression in Alzheimer’s Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005607-92 Sponsor Protocol Number: QUIDHF_v3.0_20161130 Start Date*: 2016-08-04
    Sponsor Name:QUANTUM GENOMICS
    Full Title: A Phase II randomized, placebo controlled, double-blind, multi-centre study to assess safety and efficacy of incremental doses of QGC001 in patients upon discharge or following hospitalization for ...
    Medical condition: Patient with worsening chronic heart failure with left ventricular systolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) NO (Completed) GB (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000350-26 Sponsor Protocol Number: CL09-ORY-2001 Start Date*: 2021-07-06
    Sponsor Name:Oryzon Genomics, S.A.
    Full Title: A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000482-36 Sponsor Protocol Number: CL02-ORY-1001AML Start Date*: 2018-09-07
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy.
    Medical condition: Patients with acute mieloyd leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10024349 Leukemia myeloid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-002608-16 Sponsor Protocol Number: NVALT-8B Start Date*: 2009-07-13
    Sponsor Name:UMCG
    Full Title: A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in patients with high risk for recurrence and completely resected non-small-cell lung cancer: NVAL...
    Medical condition: This is a randomized multicenter phase III study. Patient with a high SUVof the primary tumor prior to surgery will be randomised to four cycles of pemetrexed and cisplatin with or without nadropar...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002644-21 Sponsor Protocol Number: NVALT-8A Start Date*: 2009-07-13
    Sponsor Name:UMCG
    Full Title: A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low-risk for recurrence: NVALT-8A
    Medical condition: This is a randomized multicenter phase III study. Patient with a low SUV of the primary tumor prior to surgery will be randomised to four cycles of cisplatin-based chemotherapy or observation in a ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000051-24 Sponsor Protocol Number: RemiPedEntropy_v1.0 Start Date*: 2015-03-26
    Sponsor Name:Klaus Olkkola/University of Helsinki
    Full Title: The pharmacokinetics and –genomics of remifentanil, and its effects on the depth-of-anaesthesia monitors and the protein synthesis in children.
    Medical condition: otherwise healthy patients undergoing an operation necessitating general anaesthesia
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004893-32 Sponsor Protocol Number: CL03-ORY-2001 Start Date*: 2018-04-03
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: A multicentre, multinational, randomised, double-blind, placebo-controlled, 3-arm, 24-week parallel-group study to evaluate the safety, tolerability and preliminary efficacy of ORY-2001 in patients...
    Medical condition: Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003469-20 Sponsor Protocol Number: CL07-ORY-2001 Start Date*: 2020-11-06
    Sponsor Name:Oryzon Genomics S.A.
    Full Title: A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (POR...
    Medical condition: Borderline Personality Disorder (BPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10006034 Borderline personality disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-000165-23 Sponsor Protocol Number: INFORM Start Date*: 2016-10-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: ComparIsoN oF Optimal Hypertension RegiMens (Part of the Ancestry Informative Markers in Hypertension (AIM HY) Programme – AIM HY-INFORM)
    Medical condition: Cardiovascular Hemodynamics
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10005727 Blood pressure LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 09:11:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA